Skip to main content
Erschienen in: Surgery Today 5/2013

01.05.2013 | Case Report

A case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case

verfasst von: Daisuke Iitaka, Atsushi Shiozaki, Hitoshi Fujiwara, Daisuke Ichikawa, Kazuma Okamoto, Shuhei Komatsu, Yasutoshi Murayama, Hisashi Ikoma, Yoshiaki Kuriu, Masayoshi Nakanishi, Toshiya Ochiai, Yukihito Kokuba, Teruhisa Sonoyama, Eigo Otsuji

Erschienen in: Surgery Today | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

A 57-year-old male with lower esophageal cancer underwent subtotal esophagectomy with lymphadenectomy. The histopathological diagnosis was poorly differentiated squamous cell carcinoma, pT2N1M0 pStageIIB. After one course of postoperative adjuvant chemotherapy involving low-dose CDDP/5FU, a PET–CT scan obtained 12 months after surgery revealed a solitary liver metastasis in the S2 area. The patient then underwent five courses of docetaxel chemotherapy (80 mg/body, tri-weekly), and a partial response was observed. We also performed radiofrequency ablation (RFA), after which a complete response was observed. Twenty months after surgery, we detected local liver recurrence in the same position and performed additional RFA. Twenty-four months after surgery, a solitary lung metastasis was detected in the left S2 area and the patient was administered five additional courses of docetaxel therapy. Subsequently, PET–CT revealed growth of lung and liver tumors without recurrence in other areas. Twenty-nine months after surgery, we partially excised metastatic liver and lung tumors, and no subsequent recurrence has since been detected. The prognoses of patients who suffer from esophageal cancer organ recurrence are known to be extremely poor, and optimal therapeutic strategies for treating these patients have not been established. This long-term survival case suggests that multidisciplinary therapy for the treatment of liver and lung recurrence after esophagectomy is effective.
Literatur
1.
Zurück zum Zitat Tachibana M, Kinugasa S, Yoshimura H, Shibakita M, Tonomoto Y, Dhar DK, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg. 2005;189:98–109.PubMedCrossRef Tachibana M, Kinugasa S, Yoshimura H, Shibakita M, Tonomoto Y, Dhar DK, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg. 2005;189:98–109.PubMedCrossRef
2.
Zurück zum Zitat Kato H, Fukuchi M, Miyazaki T, Nakajima M, Kimura H, Faried A, et al. Classification of recurrent esophageal cancer after radical esophagectomy with two- or three-field lymphadenectomy. Anticancer Res. 2005;25:3461–7.PubMed Kato H, Fukuchi M, Miyazaki T, Nakajima M, Kimura H, Faried A, et al. Classification of recurrent esophageal cancer after radical esophagectomy with two- or three-field lymphadenectomy. Anticancer Res. 2005;25:3461–7.PubMed
3.
Zurück zum Zitat Quint LE, Hepburn LM, Francis IR, Whyte RI, Orringer MB. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer. 1995;76:1120–5.PubMedCrossRef Quint LE, Hepburn LM, Francis IR, Whyte RI, Orringer MB. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer. 1995;76:1120–5.PubMedCrossRef
4.
Zurück zum Zitat Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.PubMedCrossRef Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.PubMedCrossRef
5.
Zurück zum Zitat Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol. 2007;37:836–42.PubMedCrossRef Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol. 2007;37:836–42.PubMedCrossRef
6.
Zurück zum Zitat Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int. 2010;4:406–13.PubMedCrossRef Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int. 2010;4:406–13.PubMedCrossRef
7.
Zurück zum Zitat Shiozaki A, Yamagishi H, Itoi H, Fujiwara H, Kikuchi S, Okamoto K, et al. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep. 2005;13:667–72.PubMed Shiozaki A, Yamagishi H, Itoi H, Fujiwara H, Kikuchi S, Okamoto K, et al. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep. 2005;13:667–72.PubMed
8.
Zurück zum Zitat Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef
9.
Zurück zum Zitat Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg. 1996;83:107–11.PubMedCrossRef Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg. 1996;83:107–11.PubMedCrossRef
10.
Zurück zum Zitat Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6:229–39.PubMedCrossRef Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6:229–39.PubMedCrossRef
11.
Zurück zum Zitat Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.PubMedCrossRef Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.PubMedCrossRef
12.
Zurück zum Zitat Ahn JS, Cho SH, Kim OK, Lee JK, Yang DH, Kim YK, et al. The efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer. Cancer Res Treat. 2007;39:93–8.PubMedCrossRef Ahn JS, Cho SH, Kim OK, Lee JK, Yang DH, Kim YK, et al. The efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer. Cancer Res Treat. 2007;39:93–8.PubMedCrossRef
13.
Zurück zum Zitat Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.PubMedCrossRef Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.PubMedCrossRef
14.
Zurück zum Zitat Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study. Dis Esophagus. 2008;21:496–501.PubMedCrossRef Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study. Dis Esophagus. 2008;21:496–501.PubMedCrossRef
15.
Zurück zum Zitat Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy. 2007;53:3–449.CrossRef Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy. 2007;53:3–449.CrossRef
16.
Zurück zum Zitat Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2010;66:1159–65.PubMedCrossRef Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2010;66:1159–65.PubMedCrossRef
17.
Zurück zum Zitat Hanazaki K, Kuroda T, Wakabayashi M, Sodeyama H, Yokoyama S, Kusama J. Hepatic metastasis from esophageal cancer treated by surgical resection and hepatic arterial infusion chemotherapy. Hepatogastroenterology. 1998;45:201–5.PubMed Hanazaki K, Kuroda T, Wakabayashi M, Sodeyama H, Yokoyama S, Kusama J. Hepatic metastasis from esophageal cancer treated by surgical resection and hepatic arterial infusion chemotherapy. Hepatogastroenterology. 1998;45:201–5.PubMed
18.
Zurück zum Zitat Yamamoto T, Tachibana M, Kinugasa S, Yoshimura H, Nagasue N. Esophagectomy and hepatic arterial chemotherapy following hepatic resection for esophageal cancer with liver metastasis. J Gastroenterol. 2001;36:560–3.PubMedCrossRef Yamamoto T, Tachibana M, Kinugasa S, Yoshimura H, Nagasue N. Esophagectomy and hepatic arterial chemotherapy following hepatic resection for esophageal cancer with liver metastasis. J Gastroenterol. 2001;36:560–3.PubMedCrossRef
19.
20.
Zurück zum Zitat Pastorino U. History of the surgical management of pulmonary metastases and development of the International Registry. Semin Thorac Cardiovasc Surg. 2002;14:18–28.PubMedCrossRef Pastorino U. History of the surgical management of pulmonary metastases and development of the International Registry. Semin Thorac Cardiovasc Surg. 2002;14:18–28.PubMedCrossRef
21.
Zurück zum Zitat Chen F, Sato K, Sakai H, Miyahara R, Bando T, Okubo K, et al. Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg. 2008;7:809–12.PubMedCrossRef Chen F, Sato K, Sakai H, Miyahara R, Bando T, Okubo K, et al. Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg. 2008;7:809–12.PubMedCrossRef
22.
Zurück zum Zitat Gómez FM, Palussière J, Santos E, Tourdias T, Cornélis F, Sáiz V, et al. Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed. Clin Transl Oncol. 2009;11:28–34.PubMedCrossRef Gómez FM, Palussière J, Santos E, Tourdias T, Cornélis F, Sáiz V, et al. Radiofrequency thermocoagulation of lung tumours. Where we are, where we are headed. Clin Transl Oncol. 2009;11:28–34.PubMedCrossRef
23.
Zurück zum Zitat Todo M, Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, et al. Radiofrequency ablation for postoperative recurrent of metastatic lesions of esophageal cancer. Gan To Kagaku Ryoho. 2009;36:2459–61.PubMed Todo M, Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, et al. Radiofrequency ablation for postoperative recurrent of metastatic lesions of esophageal cancer. Gan To Kagaku Ryoho. 2009;36:2459–61.PubMed
24.
Zurück zum Zitat Lauer E, Del Pizzo JJ, Raman JD. Needlescopic ablation of small adrenal masses. Curr Urol Rep. 2009;10:73–7.PubMedCrossRef Lauer E, Del Pizzo JJ, Raman JD. Needlescopic ablation of small adrenal masses. Curr Urol Rep. 2009;10:73–7.PubMedCrossRef
25.
Zurück zum Zitat Tokairin Y, Kumagai Y, Yamazaki S. A case of postoperative liver metastasis of esophageal cancer remains in progression free after successfully resected. Gan To Kagaku Ryoho. 2009;36:2462–4.PubMed Tokairin Y, Kumagai Y, Yamazaki S. A case of postoperative liver metastasis of esophageal cancer remains in progression free after successfully resected. Gan To Kagaku Ryoho. 2009;36:2462–4.PubMed
26.
Zurück zum Zitat Nakajima Y, Nagai K, Kawano T, Inoue H, Nara S, Kumagai Y, et al. Therapeutic strategy for postoperative liver metastasis from esophageal squamous cell carcinoma; clinical efficacy of and problem with hepatic arterial infusion chemotherapy. Hepatogastroenterology. 2001;48:1652–5.PubMed Nakajima Y, Nagai K, Kawano T, Inoue H, Nara S, Kumagai Y, et al. Therapeutic strategy for postoperative liver metastasis from esophageal squamous cell carcinoma; clinical efficacy of and problem with hepatic arterial infusion chemotherapy. Hepatogastroenterology. 2001;48:1652–5.PubMed
Metadaten
Titel
A case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case
verfasst von
Daisuke Iitaka
Atsushi Shiozaki
Hitoshi Fujiwara
Daisuke Ichikawa
Kazuma Okamoto
Shuhei Komatsu
Yasutoshi Murayama
Hisashi Ikoma
Yoshiaki Kuriu
Masayoshi Nakanishi
Toshiya Ochiai
Yukihito Kokuba
Teruhisa Sonoyama
Eigo Otsuji
Publikationsdatum
01.05.2013
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 5/2013
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-012-0240-7

Weitere Artikel der Ausgabe 5/2013

Surgery Today 5/2013 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Frauen bekommen seltener eine intensive Statintherapie

30.04.2024 Statine Nachrichten

Frauen in den Niederlanden erhalten bei vergleichbarem kardiovaskulärem Risiko seltener eine intensive Statintherapie als Männer. Ihre LDL-Zielwerte erreichen sie aber fast ähnlich oft.

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.